GlobeNewswire·Oct 13, 2026, 8:00 AM ET

CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer

CG Oncology, Inc. appointed Isabel Kalofonos as Chief Commercial Officer to lead commercial strategy & execution ahead of the potential launch of cretostimogene grenadenorepvec.
Kalofonos brings over 20 years of commercial leadership experience, including recent roles as CCO at Crinetics Pharmaceuticals, ImmunoGen, Galderma, & Takeda Pharmaceuticals.
Her prior achievements include driving the successful launch of PALSONIFY™, ELAHERE®, NEMLUVIO®, & TAKHZYRO® across oncology, immunology, rare diseases, & neurology.
Kalofonos holds an M.B.A. in Entrepreneurship & Marketing from Babson College & a bachelor's degree in Industrial Engineering from Pontificia Universidad Javeriana.
Cretostimogene is an investigational oncolytic immunotherapy studied in over 400 patients with Non-Muscle Invasive Bladder Cancer (NMIBC) across Phase 3 trials BOND-003 & PIVOT-006.
The therapy has received FDA Fast Track & Breakthrough Therapy designations, with an additional Phase 2 trial (CORE-008) & an Expanded Access Program currently active in North America.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing bladder-sparing immunotherapies for patients with bladder cancer.
The press release includes standard forward-looking statements regarding potential approval, launch timing, & commercialization success, noting risks such as regulatory delays & manufacturing challenges.